Amarantus Bioscience Holdings Inc (AMBS)

[JPetroInc]

what another scam in the making...

by the way, where is the $2-Bil. MS-Precise Test these days - you know, the one AMBS shareholders paid something like $10-Mil. for in shares???

http://www.amarantus.com/news/press-releases/detail/2009/amarantus-announces-publication-of-a-clinical-study-of

Gerald E. Commissiong, President & CEO of Amarantus Bioscience Holdings, added, "Our immediate focus is to conduct a CLIA-validation study in order to make the test commercially available, and plans are being finalized in this regard. We also plan to conduct future investigational studies to determine whether MSPrecise scoring using NGS platforms may be utilized to identify clinically isolated syndrome (CIS) patients who will convert to RRMS. Additionally, a more expansive clinical study with a larger patient cohort including several sub-cohorts of RRMS patients on disease modifying therapies and OND patients is also planned."

https://www.thestreet.com/story/13235543/3/amarantus-announces-publication-of-a-clinical-study-of-mspreciser-diagnostic-for-identification-of-relapsing-remitting-multiple-sclerosis-rrms-in-the-journal-gene.html

A recent article published in The Guardian titled, "MS: four in five multiple sclerosis sufferers in UK are misdiagnosed," describes the critical unmet need of accurate and efficient MS diagnosis. In the survey of over 1,000 MS patients, 81% reported that they had at least once been misdiagnosed, with over 39% of sufferers waiting more than a year for an accurate diagnosis. A link to the article can be found here:

http://www.theguardian.com/society/2015/may/27/four-in-five-multiple-sclerosis-sufferers-in-uk-are-misdiagnosed

There are approximately 2.5 million MS patients worldwide that are currently being treated with over $14 billion in drugs. Misdiagnosis rates of over 50% have been routinely reported as the cost of each false positive diagnosis has grown to an estimated $100,000 and $250,000 per patient. This is the basis for a worldwide market estimated at over $2 billion , growing along with the cost of MS therapy.

Amarantus BioScience Holdings previously disclosed that it is exploring strategic options for Amarantus Diagnostics, including the potential sale, co-development or spinoff opportunities, to derive the full value from its neuro-diagnostics business.